Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial

Cancer

Volumn 103, Issue 10, 2005, Pages 2128-2131

  Krug, Lee M ^a,c   Crapanzano, John P ^a,b   Azzoli, Christopher G ^a   Miller, Vincent A ^a   Rizvi, Naiyer ^a   Gomez, Jorge ^a   Kris, Mark G ^a   Pizzo, Barbara ^a   Tyson, Leslie ^a   Dunne, Megan ^a   Heelan, Robert T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

C kit; Imatinib; Small cell lung carcinoma

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GROWTH INHIBITION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PARACRINE SIGNALING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; EDEMA; FATIGUE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT FAILURE;

EID: 18044381919     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21000     Document Type: Article

References (19)

1. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658-667.
2. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 1999;51:2416-2419.
3. Potti A, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003;14:894-897.
4. Naeem M, Dahiya M, Clark JI, Creech SD, Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol. 2002;33:1182-1187.
5. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 2003;9:188-194.
6. Blackball FH, Pintilie M, Michael M, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003;9:2241-2247.
7. Boldrini L, Ursino S, Gisfredi S, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res. 2004;10(12 Pt 1):4101-4108.
8. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 1996;56:370-376.
9. Heinrich M, Griffith D, Druker B, Wait C, Ott K, Zigler A. Inhibition of c-kit receptor tyrosine kinase activity by STI-571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
10. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
12. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000;19:3521-3528.
13. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319-3326.
14. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9(16 Pt 1):5880-5887.
15. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
16. Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer. 2003;39:793-799.
17. Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL Jr. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res. 2004;10:3528-3534.
18. Heinrich MC. Is KIT an important therapeutic target in small cell lung cancer? Clin Cancer Res. 2003;9:5825-5828.
19. Johnson FM, Tran HT, Johanson MJ, et al. Phase I trial of imatinib mesylate, cisplatin, and irinotecan in small cell lung cancer. Lung Cancer. 2004;46(Supp 1):S44-45.